{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:22:09Z","timestamp":1776277329424,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/eye.2016.299","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T15:08:01Z","timestamp":1484320081000},"page":"218-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Protecting retinal ganglion cells"],"prefix":"10.1038","volume":"31","author":[{"given":"T Z","family":"Khatib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K R","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"BFeye2016299_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT . The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262\u2013267.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"BFeye2016299_CR2","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.ophtha.2007.03.016","volume":"114","author":"MC Leske","year":"2007","unstructured":"Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z . Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114 (11): 1965\u20131972.","journal-title":"Ophthalmology"},{"issue":"3 Suppl.","key":"BFeye2016299_CR3","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.ajo.2004.04.058","volume":"138","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN . An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004; 138 (3 Suppl.): S19\u2013S31.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"BFeye2016299_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ajo.2013.05.027","volume":"156","author":"D Peters","year":"2013","unstructured":"Peters D, Bengtsson B, Heijl A . Lifetime risk of blindness in open-angle glaucoma. Am J Ophthalmol 2013; 156 (4): 724\u2013730.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"BFeye2016299_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ophtha.2013.09.003","volume":"121","author":"M Malihi","year":"2014","unstructured":"Malihi M, Moura Filho ER, Hodge DO, Sit AJ . Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. Ophthalmology 2014; 121 (1): 134\u2013141.","journal-title":"Ophthalmology"},{"issue":"7631","key":"BFeye2016299_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature20565","volume":"540","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Tsunekawa Y, Hernandez-Benitez R, Wu J, Zhu J, Kim EJ et al. In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration. Nature 2016; 540 (7631): 144\u2013149.","journal-title":"Nature"},{"issue":"8","key":"BFeye2016299_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nn.4340","volume":"19","author":"J-HA Lim","year":"2016","unstructured":"Lim J-HA, Stafford BK, Nguyen PL, Lien BV, Wang C, Zukor K et al. Neural activity promotes long-distance, target-specific regeneration of adult retinal axons. Nat Neurosci 2016; 19 (8): 1073\u20131084.","journal-title":"Nat Neurosci"},{"issue":"3","key":"BFeye2016299_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1167\/iovs.15-18500","volume":"57","author":"JL Goldberg","year":"2016","unstructured":"Goldberg JL, Guido W . Report on the National Eye Institute Audacious Goals Initiative: Regenerating the Optic Nerve. Invest Ophthalmol Vis Sci 2016; 57 (3): 1271\u20131275.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"#cr-split#-BFeye2016299_CR9.1","doi-asserted-by":"crossref","unstructured":"1. Barber A, Farmer K, Martin KR, Smith PD . Retinal regeneration mechanisms linked to multiple cancer molecules: a therapeutic conundrum. Prog Retin Eye Res 2016","DOI":"10.1016\/j.preteyeres.2016.08.003"},{"key":"#cr-split#-BFeye2016299_CR9.2","unstructured":"2. e-pub ahead of print 30 August 2016"},{"key":"#cr-split#-BFeye2016299_CR9.3","doi-asserted-by":"crossref","unstructured":"10.1016\/j.preteyeres.2016.08.003","DOI":"10.1016\/j.preteyeres.2016.08.003"},{"key":"BFeye2016299_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejphar.2015.03.041","volume":"759","author":"TC Burns","year":"2015","unstructured":"Burns TC, Verfaillie CM . From mice to mind: Strategies and progress in translating neuroregeneration. Eur J Pharmacol 2015; 759: 90\u2013100.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"BFeye2016299_CR11","first-page":"1618","volume":"37","author":"CK Vorwerk","year":"1996","unstructured":"Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB . Chronic low-dose glutamate is toxic to retinal ganglion cells: toxicity blocked by memantine. Invest Ophthalmol Vis Sci 1996; 37 (8): 1618\u20131624.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"BFeye2016299_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0006-8993(98)00212-1","volume":"792","author":"P Chaudhary","year":"1998","unstructured":"Chaudhary P, Ahmed F, Sharma SC . MK801\u2014a neuroprotectant in rat hypertensive eyes. Brain Res 1998; 792 (1): 154\u2013158.","journal-title":"Brain Res"},{"issue":"5","key":"BFeye2016299_CR13","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/j.1471-4159.2008.05694.x","volume":"107","author":"R Russo","year":"2008","unstructured":"Russo R, Cavaliere F, Berliocchi L, Nucci C, Gliozzi M, Mazzei C et al. Modulation of pro-survival and death-associated pathways under retinal ischemia\/reperfusion: effects of NMDA receptor blockade. J Neurochem 2008; 107 (5): 1347\u20131357.","journal-title":"J Neurochem"},{"issue":"1","key":"BFeye2016299_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3341\/kjo.2002.16.1.1","volume":"16","author":"TW Kim","year":"2002","unstructured":"Kim TW, Kim DM, Park KH, Kim H . Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia. Korean J Ophthalmol 2002; 16 (1): 1\u20137.","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"BFeye2016299_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0014-5793(95)01147-7","volume":"374","author":"O Geyer","year":"1995","unstructured":"Geyer O, Almog J, Lupu-Meiri M, Lazar M, Oron Y . Nitric oxide synthase inhibitors protect rat retina against ischemic injury. FEBS Lett 1995; 374 (3): 399\u2013402.","journal-title":"FEBS Lett"},{"issue":"17","key":"BFeye2016299_CR16","doi-asserted-by":"publisher","first-page":"9944","DOI":"10.1073\/pnas.96.17.9944","volume":"96","author":"AH Neufeld","year":"1999","unstructured":"Neufeld AH, Sawada A, Becker B . Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci USA 1999; 96 (17): 9944\u20139948.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye2016299_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.nbd.2014.07.016","volume":"71","author":"GR Howell","year":"2014","unstructured":"Howell GR, MacNicoll KH, Braine CE, Soto I, Macalinao DG, Sousa GL et al. Combinatorial targeting of early pathways profoundly inhibits neurodegeneration in a mouse model of glaucoma. Neurobiol Dis 2014; 71: 44\u201352.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"BFeye2016299_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1476-5381.2010.01103.x","volume":"162","author":"R Rosenthal","year":"2011","unstructured":"Rosenthal R, Fromm M . Endothelin antagonism as an active principle for glaucoma therapy. Br J Pharmacol 2011; 162 (4): 806\u2013816.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"BFeye2016299_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.survophthal.2008.06.006","volume":"53","author":"M Mozaffarieh","year":"2008","unstructured":"Mozaffarieh M, Grieshaber MC, Org\u00fcl S, Flammer J . The potential value of natural antioxidative treatment in glaucoma. Surv Ophthalmol 2008; 53 (5): 479\u2013505.","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"BFeye2016299_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/089771502753594936","volume":"19","author":"ZH Cheung","year":"2002","unstructured":"Cheung ZH, So K-F, Lu Q, Yip HK, Wu W, Shan JJ et al. Enhanced survival and regeneration of axotomized retinal ganglion cells by a mixture of herbal extracts. J Neurotrauma 2002; 19 (3): 369\u2013378.","journal-title":"J Neurotrauma"},{"issue":"4","key":"BFeye2016299_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000027305","volume":"212","author":"S-Y Kim","year":"1998","unstructured":"Kim S-Y, Kwak J-S, Shin J-P, Lee S-H . The protection of the retina from ischemic injury by the free radical scavenger EGb 761 and Zinc in the Cat Retina. Ophthalmologica 1998; 212 (4): 268\u2013274.","journal-title":"Ophthalmologica"},{"issue":"5","key":"BFeye2016299_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00417-005-0084-6","volume":"244","author":"N Dilsiz","year":"2006","unstructured":"Dilsiz N, Sahaboglu A, Y\u0131ld\u0131z MZ, Reichenbach A . Protective effects of various antioxidants during ischemia-reperfusion in the rat retina. Graefes Arch Clin Exp Ophthalmol 2006; 244 (5): 627\u2013633.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"BFeye2016299_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.pathophys.2004.08.001","volume":"11","author":"O Aydemir","year":"2004","unstructured":"Aydemir O, Naz\u0131ro\u011flu M, \u00c7elebi S, Y\u0131lmaz T, K\u00fckner A\u015e . Antioxidant effects of alpha-, gamma- and succinate-tocopherols in guinea pig retina during ischemia-reperfusion injury. Pathophysiology 2004; 11 (3): 167\u2013171.","journal-title":"Pathophysiology"},{"issue":"3","key":"BFeye2016299_CR24","doi-asserted-by":"publisher","first-page":"e17659","DOI":"10.1371\/journal.pone.0017659","volume":"6","author":"MS Gregory","year":"2011","unstructured":"Gregory MS, Hackett CG, Abernathy EF, Lee KS, Saff RR, Hohlbaum AM et al. Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death. PLoS One 2011; 6 (3): e17659.","journal-title":"PLoS One"},{"key":"BFeye2016299_CR25","first-page":"12","volume":"57","author":"MS Gregory-Ksander","year":"2016","unstructured":"Gregory-Ksander MS, Fei F, Marshak-Rothstein A, Ksander B, Krishnan A . Soluble Fas ligand provides long-term protection in a chronic mouse model of glaucoma by inhibiting glial activation, inflammation, and apoptosis. Invest Ophthalmol Vis Sci 2016; 57: 12.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"BFeye2016299_CR26","first-page":"2849","volume":"42","author":"E Woldemussie","year":"2001","unstructured":"Woldemussie E, Ruiz G, Wijono M, Wheeler LA . Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42 (12): 2849\u20132855.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"BFeye2016299_CR27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.exer.2008.02.008","volume":"86","author":"M Hern\u00e1ndez","year":"2008","unstructured":"Hern\u00e1ndez M, Urcola JH, Vecino E . Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp Eye Res 2008; 86 (5): 798\u2013806.","journal-title":"Exp Eye Res"},{"issue":"6","key":"BFeye2016299_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/archopht.120.6.797","volume":"120","author":"H Gao","year":"2002","unstructured":"Gao H, Qiao X, Cantor LB, WuDunn D . Upregulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002; 120 (6): 797\u2013803.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"BFeye2016299_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1017\/S0952523802191152","volume":"19","author":"RK Lai","year":"2002","unstructured":"Lai RK, Chun T, Hasson D, Lee S, Mehrbod F, Wheeler L . Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci 2002; 19 (2): 175\u2013185.","journal-title":"Vis Neurosci"},{"issue":"Suppl. 1","key":"BFeye2016299_CR30","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1177\/112067219900901S09","volume":"9","author":"LA Wheeler","year":"1999","unstructured":"Wheeler LA, Lai R, WoldeMussie E . From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1999; 9 (Suppl. 1): S17\u2013S21.","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"BFeye2016299_CR31","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1167\/iovs.08-2078","volume":"49","author":"CJ Dong","year":"2008","unstructured":"Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA . Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49 (10): 4515\u20134522.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"BFeye2016299_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","volume":"151","author":"T Krupin","year":"2011","unstructured":"Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S . A randomized trial of brimonidine versus timolol in preserving visual function: Results from the low-pressure glaucoma treatment study. Am J Ophthalmol 2011; 151 (4): 671\u2013681.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"BFeye2016299_CR33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0161-6420(00)00654-0","volume":"108","author":"AR Kent","year":"2001","unstructured":"Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D . Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 2001; 108 (4): 784\u2013787.","journal-title":"Ophthalmology"},{"key":"BFeye2016299_CR34","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0039-6257(96)82027-3","volume":"41","author":"J Burke","year":"1996","unstructured":"Burke J, Schwartz M . Preclinical evaluation of brimonidine. Surv Ophthalmol 1996; 41: S9\u201318.","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"BFeye2016299_CR35","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1167\/iovs.03-0566","volume":"45","author":"WA Hare","year":"2004","unstructured":"Hare WA, WoldeMussie E, Lai RK, Ton H, Ruiz G, Chun T et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures. Invest Ophthalmol Vis Sci 2004; 45 (8): 2625.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2016299_CR36","unstructured":"Allergan. Memantine in Patients With Chronic Glaucoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2000- [accessed on 25 September 2016]. Available at http:\/\/clinicaltrials.gov\/show\/ . NCT00141882 NLM Identifier: NCT00141882."},{"key":"BFeye2016299_CR37","unstructured":"Allergan. Memantine in Patients with Chronic Glaucoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2000- [accessed on 25 September 2016]. Available at: https:\/\/clinicaltrials.gov\/show\/NCT00168350 . NLM Identifier: NCT00168350."},{"issue":"9975","key":"BFeye2016299_CR38","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet 2015; 385 (9975): 1295\u20131304.","journal-title":"Lancet"},{"issue":"4","key":"BFeye2016299_CR39","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1167\/iovs.09-4509","volume":"51","author":"TV Johnson","year":"2010","unstructured":"Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI, Martin KR . Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci 2010; 51 (4): 2051\u20132059.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"BFeye2016299_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jcyt.2014.12.005","volume":"17","author":"E Emre","year":"2015","unstructured":"Emre E, Y\u00fcksel N, Duruksu G, Pirhan D, Suba\u015fi C, Erman G et al. Neuroprotective effects of intravitreally transplanted adipose tissue and bone marrow\u2013derived mesenchymal stem cells in an experimental ocular hypertension model. Cytotherapy 2015; 17 (5): 543\u2013559.","journal-title":"Cytotherapy"},{"key":"BFeye2016299_CR41","first-page":"1467","volume":"8","author":"Y Hu","year":"2013","unstructured":"Hu Y, Tan HB, Wang XM, Rong H, Cui HP, Cui H . Bone marrow mesenchymal stem cells protect against retinal ganglion cell loss in aged rats with glaucoma. Clin Interv Aging 2013; 8: 1467\u20131470.","journal-title":"Clin Interv Aging"},{"issue":"4","key":"BFeye2016299_CR42","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbrc.2006.03.231","volume":"344","author":"S Yu","year":"2006","unstructured":"Yu S, Tanabe T, Dezawa M, Ishikawa H, Yoshimura N . Effects of bone marrow stromal cell injection in an experimental glaucoma model. Biochem Biophys Res Commun 2006; 344 (4): 1071\u20131079.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"BFeye2016299_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/brain\/awt292","volume":"137","author":"TV Johnson","year":"2014","unstructured":"Johnson TV, Dekorver NW, Levasseur VA, Osborne A, Tassoni A, Lorber B et al. Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. Brain 2014; 137 (2): 503\u2013519.","journal-title":"Brain"},{"issue":"10","key":"BFeye2016299_CR44","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/stem.2095","volume":"33","author":"A Tassoni","year":"2015","unstructured":"Tassoni A, Gutteridge A, Barber AC, Osborne A, Martin KR . Molecular Mechanisms Mediating Retinal Reactive Gliosis Following Bone Marrow Mesenchymal Stem Cell Transplantation. Stem Cells 2015; 33 (10): 3006\u20133016.","journal-title":"Stem Cells"},{"issue":"8","key":"BFeye2016299_CR45","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/jcbfm.2014.83","volume":"34","author":"M Jin","year":"2014","unstructured":"Jin M, Kim JH, Jang E, Lee YM, Soo Han H, Woo DK et al. Lipocalin-2 deficiency attenuates neuroinflammation and brain injury after transient middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 2014; 34 (8): 1306\u20131314.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"51","key":"BFeye2016299_CR46","doi-asserted-by":"publisher","first-page":"43855","DOI":"10.1074\/jbc.M111.299248","volume":"286","author":"S Lee","year":"2011","unstructured":"Lee S, Kim JH, Kim JH, Seo JW, Han HS, Lee WH et al. Lipocalin-2 is a chemokine inducer in the central nervous system: Role of chemokine ligand 10 (CXCL10) in lipocalin-2-induced cell migration. J Biol Chem 2011; 286 (51): 43855\u201343870.","journal-title":"J Biol Chem"},{"key":"BFeye2016299_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.exer.2013.10.023","volume":"118","author":"A Tzameret","year":"2014","unstructured":"Tzameret A, Sher I, Belkin M, Treves AJ, Meir A, Nagler A et al. Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Exp Eye Res 2014; 118: 135\u2013144.","journal-title":"Exp Eye Res"},{"key":"#cr-split#-BFeye2016299_CR48.1","doi-asserted-by":"crossref","unstructured":"6. Kim JY, You YS, Kim SH, Kwon OW . Epiretinal Membrane Formation After Intravitreal Autologous Stem Cell Implantation In A Retinitis Pigmentosa Patient. Retin Cases Brief Rep 2016","DOI":"10.1097\/ICB.0000000000000327"},{"key":"#cr-split#-BFeye2016299_CR48.2","doi-asserted-by":"crossref","unstructured":"10.1097\/ICB.0000000000000327","DOI":"10.1097\/ICB.0000000000000327"},{"issue":"4","key":"BFeye2016299_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8 (4): 315\u2013317.","journal-title":"Cytotherapy"},{"key":"BFeye2016299_CR50","unstructured":"University of Sao Paulo. Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2000- [accessed on 26 September 2016]. Available at http:\/\/clinicaltrials.gov\/show\/NCT02330978 . NLM Identifier: NCT02330978."},{"key":"BFeye2016299_CR51","unstructured":"Retina Associates of South Florida. Stem Cell Ophthalmology Treatment Study (SCOTS). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2000- [accessed on 26 September 2016]. Available at http:\/\/clinicaltrials.gov\/show\/NCT01920867 . NLM Identifier: NCT01920867."},{"key":"BFeye2016299_CR52","unstructured":"Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federation. Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2000- [accessed on 26 September 2016]. Available at http:\/\/clinicaltrials.gov\/show\/NCT02144103 . NLM Identifier: NCT02144103."},{"issue":"20","key":"BFeye2016299_CR53","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","volume":"372","author":"JWB Bainbridge","year":"2015","unstructured":"Bainbridge JWB, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C et al. Long-term effect of gene therapy on Leber\u2019s congenital amaurosis. N Engl J Med 2015; 372 (20): 1887\u20131897.","journal-title":"N Engl J Med"},{"issue":"20","key":"BFeye2016299_CR54","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1056\/NEJMc1509501","volume":"374","author":"TL Edwards","year":"2016","unstructured":"Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL, Tolmachova T et al. Visual acuity after retinal gene therapy for choroideremia. N Engl J Med 2016; 374 (20): 1996\u20131998.","journal-title":"N Engl J Med"},{"key":"BFeye2016299_CR55","unstructured":"Gensight Biologics. Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2000- [accessed on 26 September 2016]. Available at https:\/\/clinicaltrials.gov\/show\/NCT02064569 . NLM Identifier: NCT02064569."},{"key":"BFeye2016299_CR56","doi-asserted-by":"publisher","first-page":"21587","DOI":"10.1038\/srep21587","volume":"6","author":"X Wan","year":"2016","unstructured":"Wan X, Pei H, Zhao M, Yang S, Hu W, He H et al. Efficacy and Safety of rAAV2-ND4 Treatment for Leber\u2019s Hereditary Optic Neuropathy. Sci Rep 2016; 6: 21587.","journal-title":"Sci Rep"},{"key":"BFeye2016299_CR57","unstructured":"Gensight Biologics. Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation (RESCUE). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2000- [accessed on 26 September 2016]. Available at https:\/\/clinicaltrials.gov\/show\/NCT02652767 . NLM Identifier: NCT02652767."},{"key":"BFeye2016299_CR58","unstructured":"GenSight Biologics. Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2000- [accessed on 26 September 2016]. Available at https:\/\/clinicaltrials.gov\/show\/NCT02652780 . NLM Identifier: NCT02652780."},{"issue":"10","key":"BFeye2016299_CR59","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1167\/iovs.02-1332","volume":"44","author":"KR Martin","year":"2003","unstructured":"Martin KR, Quigley HA, Zack DJ, Levkovitch-Verbin H, Kielczewski J, Valenta D et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003; 44 (10): 4357\u20134365.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"BFeye2016299_CR60","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1167\/iovs.08-3013","volume":"50","author":"ME Pease","year":"2009","unstructured":"Pease ME, Zack DJ, Berlinicke C, Bloom K, Cone F, Wang Y et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50 (5): 2194\u20132200.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2016299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2016299","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2016299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:29:15Z","timestamp":1684430955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2016299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFeye2016299"],"URL":"https:\/\/doi.org\/10.1038\/eye.2016.299","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]},"assertion":[{"value":"11 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KRM is a consultant to Quethera Ltd. TZK declares no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}